Cargando...

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of treatment in different patient categories (first and second line of treatment). Howe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ascierto, Paolo A, Marincola, Francesco M, Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2011
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3262765/
https://ncbi.nlm.nih.gov/pubmed/22077981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-196
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!